ArticleCirculation. Population health and outcomes2026
Transcatheter Aortic Valve Replacement (TAVR) in Medicare Advantage and Medicare Fee-for-Service: Differences in Patient Characteristics, Utilization, and Outcomes.
Article in Circulation. Population health and outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundOver half of Medicare beneficiaries are enrolled in privately administered Medicare Advantage (MA) plans, and aortic stenosis predominantly affects older patients. In this study, we evaluated whether differences in care delivery between MA and fee-for-service (FFS) Medicare contribute to cardiovascular outcomes after transcatheter aortic valve replacement (TAVR).
methodsMedicare patients who underwent TAVR from January 1, 2018, to December 31, 2022, were eligible for cohort inclusion. TAVR utilization rates in MA and FFS were calculated as the age- and sex-standardized number of procedures per 10 000 person-years. Patient characteristics were compared between MA and FFS using standardized mean differences (SMDs), with an SMD ≥10 considered meaningful. The association of MA versus FFS enrollment with 30-day and 1-year outcomes was assessed using logistic and Cox regression models, respectively.
resultsAmong the 317 630 patients (64.4% FFS, 35.6% MA) undergoing TAVR, the mean age was 80.6±7.0 years, and 55.1% were male. TAVR utilization rates were similar between MA and FFS, with 11.2 TAVRs/10 000 person-years in FFS compared with 11.7 TAVRs/10 000 person-years in MA by the end of the study. Compared with FFS patients, MA patients were more likely to be Black (5.4% versus 3.0%; SMD, -11.9) and dual-enrolled in Medicaid (13.7% versus 8.6%; SMD, -16.3). Comorbidity profiles were similar (SMD,
conclusionsDespite similar clinical profiles and TAVR utilization, MA patients appeared to experience better 30-day and 1-year outcomes than FFS patients. Differences in care delivery may contribute, but future studies are needed to understand differences in outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.